Senotherapeutics / Institute for Human Optimization
A physician-guided approach to one of the biological hallmarks of aging.
As we age, damaged and dysfunctional cells can accumulate rather than being cleared normally. These senescent cells may release inflammatory and signaling molecules that affect surrounding tissues, a phenomenon increasingly studied in aging, metabolic disease, musculoskeletal health, and other age-related conditions.
At the Institute for Human Optimization, senotherapeutic strategies are considered selectively within a broader longevity medicine program, not as a universal anti-aging treatment.
Senescence is a state in which a cell stops dividing in response to stress or damage but remains active, sending signals to the tissue around it.
Divides and functions normally within its tissue.
DNA damage, oxidative stress, or other cellular insults.
Stops dividing but is not cleared normally, so it can accumulate.
Releases inflammatory and signaling molecules.
A persistent signaling environment that may affect surrounding tissue.
Cellular senescence is not inherently harmful. It plays important roles in processes including wound healing and tumor suppression. The concern is the age-related accumulation of senescent cells and their persistent signaling environment.
Wound healing and tumor suppression.
Accumulation with age and a persistent inflammatory signaling environment.
Senolytic compounds are being investigated for their ability to selectively promote the clearance of certain senescent cells.
Because senescent cells take time to accumulate again, investigational approaches generally use intermittent exposure rather than continuous treatment.
Senomorphic strategies take a different approach. Rather than eliminating senescent cells, they attempt to modify pathways involved in the inflammatory secretions associated with cellular senescence, including the senescence-associated secretory phenotype (SASP).
Both strategies remain areas of active research. Neither is a proven treatment for aging.
Cellular senescence is recognized as one of the biological hallmarks of aging. Researchers are studying how senescent-cell biology relates to several areas of health.
Insulin sensitivity and fat-tissue biology.
Bone, joint, and muscle tissue.
Immune function and chronic, low-grade inflammation.
Blood vessel function and vascular aging.
Strength, mobility, and resilience with age.
Research into brain aging.
These associations do not mean that senolytic therapy has been proven to prevent or treat these conditions.
The hallmarks of agingSenescent cells serve biological functions, and current research does not support indiscriminate senolytic treatment for every healthy adult.
“How old are you?”
“Is there evidence that targeting cellular senescence makes biological and clinical sense for you?”
The focus is on patients whose evaluation suggests a higher senescent-cell burden, rather than treating everyone.
Each stage has to justify the next. Many patients complete the evaluation and never proceed to treatment, and that is a valid outcome.
We begin by understanding your biology, health history, and goals before any intervention is considered.
Evaluation may include laboratory testing such as a CBC and CMP, metabolic and inflammatory markers, functional measurements, DEXA, and, where appropriate, research-grade aging or senescence markers.
Not every patient proceeds.
The physician evaluates potential benefit, contraindications, medication interactions, and whether there is sufficient rationale for intervention.
Depending on your biology and medical history, the physician may consider different investigational approaches.
An investigational senolytic combination with some of the most developed human translational evidence for senescent-cell targeting.
A naturally occurring flavonoid under investigation as a senolytic, with an emerging but currently limited human evidence base.
An mTOR-modulating medication being studied in aging biology that may influence pathways associated with cellular senescence and the SASP.
None of these agents is FDA approved to treat aging. Agent selection, dosing, and scheduling are individualized by your physician.
If we intervene in biology, we measure biology.
Treatment isn’t simply prescribed and forgotten. Patients undergo appropriate safety monitoring after any new agent is introduced, followed by longitudinal reassessment against their own baseline. Together, you and your physician decide whether to continue, adjust, or stop.
Outcomes are interpreted longitudinally and in clinical context, not as isolated numbers.
Senotherapeutics represent an emerging area of geroscience focused on the biology of cellular senescence. Early human studies have demonstrated measurable biological activity, while ongoing clinical research continues to evaluate how these changes may translate into improvements in health, function, and healthy aging.
An evolving field moving from biological discovery toward clinical translation.
Human studies of certain investigational senolytic approaches have demonstrated measurable changes in markers associated with cellular senescence and the senescence-associated secretory phenotype.
Early clinical studies have reported signals across select functional and biological outcomes. Results vary by population and endpoint, reinforcing the importance of thoughtful patient selection and continued research.
Whether targeting cellular senescence can meaningfully influence long-term healthspan or lifespan in humans remains an important area of investigation. Long-term clinical outcomes have not yet been established.
Follow the evidence as it evolves, select patients thoughtfully, measure outcomes, and adjust accordingly.
Senotherapeutic strategies remain investigational for longevity and healthy aging. Evidence summaries reflect the current state of research and are reviewed as new clinical data emerge.
Some senotherapeutic approaches involve prescription medications with meaningful pharmacology, drug interactions, and potential adverse effects.
Considerations may include
Appropriate evaluation may include
Do not attempt senolytic protocols obtained online without appropriate medical supervision.
Understand your baseline.
Set priorities from your data.
Senotherapeutics may be one option here.
Track change over time.
Senotherapeutics may represent one component of a broader strategy addressing:
